Cargando…

The bevacizumab experience in advanced renal cell carcinoma

Bevacizumab in combination with interferon alfa is now approved for treatment-naïve advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response rates of 30% and progression-free survival rates of 9–10 months are comparable to the other approved first-line multityrosine kina...

Descripción completa

Detalles Bibliográficos
Autores principales: Harshman, Lauren C, Srinivas, Sandy
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2962304/
https://www.ncbi.nlm.nih.gov/pubmed/21049084

Ejemplares similares